[email protected]

Login

Research papers

Lancet Gastroenterol Hepatol . 2025 Jun;10(6):550-561. DOI: 10.1016/S2468-1253(25)00026-3
Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE)

Gut Published Online First: 30 April 2025. doi: 10.1136/gutjnl-2025-335023
British Society of Gastroenterology guidelines on colorectal surveillance in inflammatory bowel disease

PLoS Genet . 2025 Apr 10;21(4):e1011599. doi: 10.1371/journal.pgen.1011599
The identification of blood-derived response eQTLs reveals complex effects of regulatory variants on inflammatory and infectious disease risk

Gut . 2025 Mar 6;74(4):652-668. doi: 10.1136/gutjnl-2024-332504.
Targeting TL1A and DR3: the new frontier of anti-cytokine therapy in IBD

Gut 2025;74:312-321
Recent advances in clinical practice: mastering the challenge—managing IBS symptoms in IBD

Clin Gastroenterol Hepatol . 2025 Feb;23(2):341-350.e6. doi: 10.1016/j.cgh.2024.07.010. Epub 2024 Jul 31.
Endoscopic, Histologic, and Composite Endpoints in Patients With Ulcerative Colitis Treated With Etrasimod

The Lancet, Volume 404, Issue 10470, 2423 - 2436
Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease

The Lancet Gastroenterology & Hepatology, online November 18, 2024, https://doi.org/10.1016/S2468-1253(24)00317-0
Vedolizumab to prevent postoperative recurrence of Crohn's disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial

‹
1
2
3
4
5
6
›